Form 4 for OGEN ORAGENICS INC
Accepted 2025-12-15 00:00:00 ET · period of report 2025-12-11 · accession 0001382225-25-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-15 | 2025-12-12 | OGEN | Telling Fred | Dir | S - Sale | $0.94 | -210 | 34.5K | -0.6% | -$197.40 |
| D | 2025-12-15 | 2025-12-11 | OGEN | Telling Fred | Dir | A - Grant | $0.00 | +125.0K | 125.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-12 | S | D | 210 | $0.94 | 34,538 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.9440 to $0.9451. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| 2 | Derivative | Non-Employee Director Option (Right to Buy) | 2025-12-11 | A | A | 125,000 | $0.00 | 125,000 | D | $0.93 · 2025-12-11 to 2035-12-11 | 125,000 Common Stock | (F2) Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. |